Opendata, web and dolomites

SPELITEC SIGNED

Sequence sPecific ELImination of shiga-Toxin E. Coli

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SPELITEC project word cloud

Explore the words cloud of the SPELITEC project. It provides you a very rough idea of what is the project "SPELITEC" about.

humans    bacterial    clinical    children    strains    stecs    spectrum    batch    eliminates    safety    variants    team    consisting    bacteria    pharmacological    medical    mechanism    toxicity    market    orphan    designed    hospitalized    therapeutic    patients    young    unmet    stec    license    safe    companies    company    finalise    elimination    multivalent    shiga    multinational    transfusions    eligo    solid    treatments    drug    preclinical    tests    eb003    fatal    treatment    spelitec    receive    individualised    symptomatic    conducting    authorization    alternative    healthy    uremic    patient    indication    microbiota    orally    selectively    producing    exert    administered    populations       acquisition    release    haemolytic    complications    coli    resistance    receptors    gel    background    coupled    mix    antibodies    launch    model    complete    initiate    nature    plans    liquid    disrupting    empts    antibiotic    rehydration    infections    validation    inducing    toxin    dialysis    mutation    progression    animals    action    disease    validate    capsid    first    validated    toxins    clinically    paediatric    primary    compound    pharma    business   

Project "SPELITEC" data sheet

The following table provides information about the project.

Coordinator
ELIGO BIOSCIENCE 

Organization address
address: 29 RUE FAUBOURG SAINT JACQUES PEPIN
city: PARIS
postcode: 75014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙948˙250 €
 EC max contribution 2˙763˙775 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELIGO BIOSCIENCE FR (PARIS) coordinator 2˙763˙775.00

Map

 Project objective

SPELITEC is the first treatment for Shiga toxin-producing E. coli (STEC) infections, which affects primary young children and can be fatal in 1-5% of the cases. Currently there is no validated safe treatment: hospitalized patients receive only symptomatic treatments consisting of rehydration coupled with transfusions and dialysis for haemolytic uremic complications. The SPELITEC program is designed to finalise preclinical and initiate clinical studies for elimination of STEC bacteria (Shiga-toxin producing E. coli) in paediatric populations with a dedicated product: EB003. EB003 selectively eliminates STEC bacteria early in the disease progression; it is not expected to exert any toxicity in humans or animals; it is a multivalent mix of different capsid variants allows to target the whole spectrum of clinically relevant strains and pre-empts the acquisition of resistance through mutation of bacterial receptors; it is administered orally by a liquid/gel which is patient-friendly and adapted to young children and it represents a cost-effective alternative to antibodies against Shiga toxins. Our technology is the only one allowing the specific elimination of STECs without toxin release and without disrupting microbiota and inducing antibiotic resistance. Eligo will complete early drug development, which should ensure market authorization given the orphan and unmet medical need nature of the indication, and plans to out-license the compound to an established pharma company that will launch the product on the market. The management team of Eligo has solid business and technical management experience in multinational companies and a very strong drug development background. During the Phase 2 project we will validate this new individualised therapeutic approach and mechanism of action by conducting the validation of the pharmacological model, the production of a clinical batch and the safety tests in healthy animals.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPELITEC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPELITEC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More